Autolus Therapeutics plc (NASDAQ:AUTL) Shares Acquired by Millennium Management LLC

Millennium Management LLC boosted its stake in Autolus Therapeutics plc (NASDAQ:AUTL) by 113.7% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 813,031 shares of the company’s stock after acquiring an additional 432,503 shares during the quarter. Millennium Management LLC owned 0.31% of Autolus Therapeutics worth $2,829,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. ProShare Advisors LLC acquired a new stake in Autolus Therapeutics in the 2nd quarter valued at $43,000. Daiwa Securities Group Inc. boosted its stake in Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after purchasing an additional 15,293 shares during the last quarter. Bayesian Capital Management LP acquired a new stake in Autolus Therapeutics during the 1st quarter worth $100,000. B. Riley Wealth Advisors Inc. acquired a new stake in Autolus Therapeutics during the 1st quarter worth $108,000. Finally, SG Americas Securities LLC acquired a new stake in Autolus Therapeutics during the 1st quarter worth $127,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Stock Performance

NASDAQ AUTL opened at $4.18 on Tuesday. The company has a market cap of $1.11 billion, a P/E ratio of -3.48 and a beta of 2.04. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55. The stock has a 50-day moving average of $3.88 and a two-hundred day moving average of $4.14. Autolus Therapeutics plc has a 1-year low of $2.21 and a 1-year high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). As a group, analysts anticipate that Autolus Therapeutics plc will post -0.84 EPS for the current year.

Analysts Set New Price Targets

Separately, Needham & Company LLC reiterated a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a report on Monday, June 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Autolus Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $8.70.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.